Skip to main content
Pure Biologics S.A. logo

Pure Biologics S.A. — Investor Relations & Filings

Ticker · PUR ISIN · PLPRBLG00010 LEI · 2594002TXS19AUYHIF82 WAR Manufacturing
Open in API
Filings indexed 515 across all filing types
Latest filing 2025-05-15 Interim / Quarterly Rep…
Country PL Poland
Listing WAR PUR

About Pure Biologics S.A.

https://purebiologics.com/

Pure Biologics S.A. is a biopharmaceutical company engaged in the discovery and development of novel biological drugs and non-systemic therapies. The company leverages its expertise in antibody and aptamer technologies to create innovative treatments. Its therapeutic portfolio is primarily focused on immuno-oncology. A key aspect of its strategy is the development of original, non-generic and non-biosimilar, biological drug candidates.

Recent filings

Filing Released Lang Actions
Jednostkowy raport kwartalny za 1Q2025 Pure Biologics S.A.
Interim / Quarterly Report Classification · 100% confidence The document is a 'Jednostkowy raport kwartalny' (Standalone Quarterly Report) for the period 01.01.2025 - 31.03.2025. It contains detailed sections on company management, business operations, R&D projects, and financial data. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Polish
Sprawozdanie niezależnego biegłego rewidenta z badania sprawozdania finansowego za rok obrotowy 2024 - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists almost entirely of XML signature blocks, specifically containing elements like 'Signature', 'SignedInfo', 'SignatureValue', 'KeyInfo', 'X509Data', and 'Object' with 'QualifyingProperties'. This structure is characteristic of digitally signed documents, often used to verify the authenticity and integrity of official filings or reports. The presence of Polish identifiers (like 'VATPL', 'Enigma Systemy Ochrony Informacji Sp. z o.o.', and 'Narodowy Bank Polski') suggests a Polish regulatory context. Since the content is the signature block itself and not the underlying report content (like financial tables or narrative discussion), and it doesn't explicitly announce a report release (which would point to RPA or RNS), the most appropriate classification for a document whose primary visible content is a digital signature/verification structure, without clear context of the underlying filing type, is the general fallback category for regulatory filings that don't fit elsewhere.
2025-04-30 Polish
Sprawozdanie niezależnego biegłego rewidenta z badania sprawozdania finansowego za rok obrotowy 2024
Audit Report / Information Classification · 95% confidence The document text provided is an HTML structure containing CSS styles and font definitions, likely resulting from a PDF conversion process (indicated by 'pdf2htmlEX' in the CSS and the title 'PureBiologics_SzB_ODMOWA_JSF_MSSF_2024.xhtml'). The document length is very large (1,347,952 characters), suggesting it contains the full content of a report, not just a brief announcement. The title contains 'MSSF' (likely IFRS in Polish context) and '2024', suggesting a financial report for a specific period. Given the substantial length and the nature of the content being a converted report rather than a short announcement about a report, it is most likely a comprehensive financial report. Since it is not explicitly labeled as a 10-K (Annual Report), and the title suggests a specific, possibly interim or specialized report (ODMOWA_JSF_MSSF), the most appropriate classification among the comprehensive report options is Interim / Quarterly Report (IR), or if it's a full annual report disguised in a non-standard format, 10-K. However, without explicit 'Annual Report' or '10-K' keywords, and given the context of MSSF (International Financial Reporting Standards), this points towards a formal financial filing. Since the document is extremely long and appears to be the full content, it is classified as a comprehensive report. If it were a standard US filing, it would be 10-K. For non-US comprehensive reports, IR is often used for periods shorter than a year, but given the size, it represents the full financial statement set. I will lean towards the most comprehensive report type available that isn't the specific 10-K form, which is IR, or consider it a general Financial Statement (FS) if it were shorter, but given the size, it's a full report. Since the content is clearly a converted financial document, and it's not a short announcement (ruling out RPA/RNS based on the 'Menu vs Meal' rule), and it's not explicitly an Annual Report (10-K), I will classify it as an Interim Report (IR) as a strong candidate for a comprehensive period report, or potentially a general Financial Supplement Data (XLSX) if the content was structured data, but the HTML structure suggests rendered text/tables. Given the context of MSSF, it is a formal financial statement. I will select IR as the best fit for a comprehensive financial report that isn't the 10-K. FY 2024
2025-04-30 Polish
Jednostkowe sprawozdanie finansowe Pure Biologics S.A. za rok obrotowy 2024 - podpisy
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of XML signature blocks (ds:Signature, KeyInfo, SignatureValue, Object, QualifyingProperties) used to digitally sign an external document referenced by URI="PureBiologics_JSF-2024-12-31-0-pl.xhtml". The presence of multiple digital signatures and associated metadata (like SigningTime: 2025-04-30T15:40:19.685Z) indicates this is not the primary financial report itself, but rather a container or wrapper file confirming the authenticity of another document. Since the content is purely technical metadata about signing and does not contain financial results, management discussion, or specific regulatory disclosures (like 10-K, ER, IR), it falls best into the general regulatory/miscellaneous category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for technical or administrative filings that don't fit specific financial reporting codes. It is definitely not an ER, 10-K, or IR, and it is too long and complex to be a simple Report Publication Announcement (RPA) which usually just announces the availability of the main report.
2025-04-30 Polish
Jednostkowe sprawozdanie finansowe Pure Biologics S.A. za rok obrotowy 2024
Audit Report / Information Classification · 95% confidence The document text provided is extremely short (after truncation) and consists almost entirely of HTML/CSS structure, font definitions, and metadata, including a title: "PureBiologics_JSF-2024-12-31-0-pl.xhtml". The presence of an XHTML structure and a filename ending in a date (2024-12-31) suggests this is a wrapper or a converted file of a regulatory submission, likely an XBRL filing given the mention of "Consolia XBRL Tools". However, the content itself does not contain the substance of a financial report (like 10-K, IR, or ER). Since it is a technical wrapper/conversion of a filing, and it doesn't fit any specific report type (like 10-K, IR, ER, etc.), the most appropriate classification based on the provided definitions is the general fallback category for miscellaneous regulatory filings that don't fit elsewhere, which is 'RNS' (Regulatory Filings). The document length is also very small relative to the full document size (17MB truncated to 15KB), supporting the idea that this is an announcement or wrapper rather than the full report itself, although RPA is usually for announcing the publication of a report, not the technical file itself. Given the context of a database classifying filings, RNS is the best fit for an underlying technical filing wrapper. FY 2024
2025-04-30 Polish
Jednostkowy raport roczny Pure Biologics S.A. za okres 01.01-31.12.2024 - podpisy
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of XML structures related to digital signatures (Signature, SignedInfo, DigestValue, X509Data, etc.). This structure is typical of electronically filed documents that have been digitally signed for authenticity and integrity, often accompanying a primary filing or serving as a standalone verification artifact. Crucially, the document contains a reference to a file named "PureBiologics_JRR-2024-12-31-0-pl.xhtml" and a signing time of '2025-04-30T15:46:55Z'. The presence of a specific file name and the digital signature metadata strongly suggest this is not the primary financial report itself (like 10-K or IR), but rather the signature block attached to a filing. Given the options, this metadata-heavy, signed artifact does not fit neatly into standard content categories (ER, IR, 10-K, IP, etc.). It is a regulatory artifact, but since it's not a standard announcement type, the most appropriate fallback category for miscellaneous regulatory/verification documents that don't fit elsewhere is 'Regulatory Filings' (RNS). The document length (9998 chars) is substantial, but the content is purely structural/metadata, not narrative financial reporting.
2025-04-30 Polish

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.